Shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) shot up 3.7% during mid-day trading on Friday . The company traded as high as $3.78 and last traded at $3.63, with a volume of 69,455 shares traded. The stock had previously closed at $3.50.

A number of brokerages recently issued reports on CATB. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Saturday, May 14th. Cowen and Company reiterated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Saturday, May 14th. Zacks Investment Research lowered shares of Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Wedbush reiterated an “outperform” rating and set a $27.00 target price on shares of Catabasis Pharmaceuticls in a research note on Friday, May 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.05.

The firm’s 50 day moving average is $4.17 and its 200-day moving average is $5.17. The firm’s market capitalization is $54.58 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its earnings results on Thursday, May 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.03. Equities research analysts forecast that Catabasis Pharmaceuticls Inc. will post ($2.52) EPS for the current year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.